The Hindu Business Line : Themis, Aventis in tech-transfer deal

Mumbai, July 27 Themis Laboratories Pvt Ltd has signed a technology transfer agreement with Aventis Pharma Ltd for fixed-dose combinations using two of its best selling medicines, glibenclamide (Daonil) and glimepiride (Amaryl).

The two drugs would be combined individually with sustained-release metformin through a technology developed by Themis Laboratories, and the product would be used in the treatment of Type 2 diabetes.

Daonil and Amaryl are among the best selling products from the Sanofi-Aventis research pipeline and were available as single-ingredient drugs for the treatment of Type 2 diabetes. Metformin is another ingredient used in diabetes medicines.

Fixed-dose need

There was a need to introduce a fixed dose combination for both drugs with metformin sustained-release formulation through a technology that would ensure the required bioavailability, a note from Sanofi-Aventis said.

As per the agreement, Aventis Pharma (part of the Sanofi-Aventis group) will retain exclusive rights for these combinations developed by Themis.

In a company statement, Dr Shailesh Ayyangar, Managing Director of Aventis Pharma Ltd, said that the technology transfer agreement with Themis has enabled Aventis Pharma to introduce Daonil M and Amaryl M in India to give doctors and patients access to quality combination products with indigenously developed patented technology of Themis Laboratories.

Patented tech

This will widen their portfolio of drugs to manage Type 2 diabetes at various disease progression points. “The new fixed-dose combination products use, on an exclusive basis, a patented technology developed by Themis Laboratories that ensures the required bio-availability of individual components and improves convenience and compliance with therapy,” he said.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page